Company intelligence / Profile preview

Novalogy

Walnut, California, United States

Ownership: Private
Development stage: Commercial

Overview

Novalogy’s flagship product AYO is a wearable light therapy device designed to regulate circadian rhythms and improve sleep quality, boost energy levels, and reduce jet lag. The technology is based on over 20 years of clinical research into blue-turquoise light’s effects on melatonin suppression. According to company data, 89% of users report improved energy and better sleep. The product is fully commercialized with global distribution.

Therapeutic areas: OtherEndocrinologyNeurology
Modalities: DeviceNon-pharmacological therapyLight therapy device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

AYO

Commercial

Indications: Sleep disorders, Jet lag, Energy levels

Beyond the preview

Go deeper on Novalogy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novalogy.

Explore the full profile